Renin angiotensin system-induced muscle wasting: putative mechanisms and implications for clinicians

Baris Afsar1,2, Rengin Elsurer Afsar3,4, Yasar Caliskan4

  • 1Department of Nephrology, School of Medicine, Suleyman Demirel University, Isparta, Turkey. afsarbrs@yahoo.com.

Insights

The Renin Angiotensin System (RAS) impacts muscle wasting. Its classical pathway, via Angiotensin II (AngII), promotes muscle loss, while the non-classical pathway, via Angiotensin 1-7, offers protection.

Area of Science:

  • Physiology
  • Molecular Biology
  • Gerontology

Background:

  • The Renin Angiotensin System (RAS) plays a critical role in regulating physiological processes.
  • Dysregulation of the RAS is implicated in various pathological conditions, including muscle wasting and sarcopenia.
  • The RAS comprises distinct classical and non-classical pathways with opposing effects on skeletal muscle.

Purpose of the Study:

  • To review the multifaceted mechanisms by which the classical and non-classical RAS pathways influence muscle wasting.
  • To explore the potential clinical implications of targeting the RAS for sarcopenia treatment.
  • To identify knowledge gaps and suggest future research directions in RAS-mediated muscle atrophy.

Main Methods:

  • Literature review of studies investigating the Renin Angiotensin System and its components.
  • Analysis of molecular and cellular mechanisms underlying RAS-induced muscle wasting.
  • Synthesis of evidence regarding the protective role of the non-classical RAS pathway.

Main Results:

  • The classical RAS pathway, mediated by Angiotensin II (AngII) and AT1 receptors, promotes muscle wasting through reduced food intake, increased proteolysis, apoptosis, inflammation, oxidative stress, and impaired mitochondrial function.
  • The non-classical RAS pathway, involving Angiotensin 1-7 and the Mas receptor, counteracts these catabolic effects, offering protection against sarcopenia.
  • Specific molecular targets include orexin, neuropeptide Y, IGF-1, mTOR, FOXO, caspase, TNF-α, and IL-6.

Conclusions:

  • The balance between classical and non-classical RAS pathways is crucial for maintaining skeletal muscle mass and function.
  • Targeting specific components of the RAS presents a promising therapeutic strategy for combating muscle wasting and sarcopenia.
  • Further research is needed to fully elucidate the complex interactions within the RAS and its clinical applications.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
585
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
617
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
711